How to Get Lantus in Pennsylvania: Prescriptions, Telehealth, and Pharmacies

What Is Insulin Glargine and Why Pennsylvania Residents Need a Prescription

Insulin glargine is a long-acting basal insulin analog approved by the FDA for once-daily subcutaneous injection in adults and pediatric patients with type 1 diabetes, and in adults with type 2 diabetes. Lantus received its original FDA approval in 2000, and Sanofi markets it in 10 mL vials (100 units/mL) and 3 mL SoloStar prefilled pens.

Pennsylvania, like every other U.S. state, classifies insulin glargine as a prescription-only medication under 21 C.F.R. § 310.3. A valid prescription from a Pennsylvania-licensed prescriber is the only legal path to dispensing. There is no over-the-counter route for Lantus specifically, though some older human insulins are sold OTC. Biosimilar insulin glargines, including Basaglar (Eli Lilly) and Rezvoglar (Eli Lilly), carry the same prescription requirement and use the same active ingredient. The FDA's approved biosimilar list confirms interchangeable status for several glargine products.

The American Diabetes Association's 2024 Standards of Care recommend basal insulin as a foundational therapy when A1C targets are not met with oral agents alone in type 2 diabetes, and as lifelong therapy for virtually all type 1 diabetes. This clinical context means tens of thousands of Pennsylvanians require a reliable, repeatable prescription pathway each year.

How to Get a Lantus Prescription in Pennsylvania

The fastest route for most Pennsylvania residents is a telehealth appointment with a Pennsylvania-licensed prescriber. Pennsylvania law permits synchronous audio-video telehealth prescribing for insulin under Act 44 of 2021 (PA Telehealth Law), which established a permanent framework for telehealth services. A prescriber may issue a Lantus prescription after a clinically adequate evaluation conducted via secure video.

For a first prescription, most prescribers require:

1. A confirmed diabetes diagnosis (type 1 or type 2) supported by prior lab records or a new in-office A1C.
2. Review of current medications, kidney function (serum creatinine/eGFR), and hypoglycemia history.
3. A discussion of injection technique, glucose monitoring plan, and hypoglycemia rescue (glucagon or glucose tablets).

The ADA 2024 Standards recommend that basal insulin be started at 10 units per day or 0.1, 0.2 units per kg per day, then titrated based on fasting glucose. Your prescriber will individualize this. Refills are generally authorized every 30 to 90 days depending on supply dispensed.

Pennsylvania physicians (MDs and DOs), nurse practitioners (CRNP), and physician assistants (PA-C) all hold independent or collaborative prescribing authority for Schedule II-exempt medications including insulin. The Pennsylvania State Board of Nursing confirms CRNP prescribing authority under a collaborative agreement or independent practice depending on the practice setting.

Telehealth Providers Prescribing Lantus in Pennsylvania

Pennsylvania has among the more favorable telehealth environments in the mid-Atlantic region. Since Act 44 of 2021, Pennsylvania maintains parity requirements meaning commercial insurers must reimburse covered telehealth visits at rates comparable to in-person care. This has expanded the number of endocrinologists, primary care physicians, and diabetes-focused telehealth platforms operating within the state.

A telehealth appointment for Lantus typically follows this sequence. First, complete an online intake form disclosing your diabetes diagnosis, current A1C if available, existing medications, and insurance information. Second, the platform assigns a Pennsylvania-licensed prescriber for a synchronous video visit lasting 15 to 30 minutes. Third, if appropriate, the prescriber sends an electronic prescription (e-Rx) directly to your chosen Pennsylvania pharmacy or to a mail-order pharmacy licensed in the state. CMS confirms that e-prescribing for non-controlled substances has no federal barrier, and Pennsylvania adopted electronic prescribing standards under Act 191 of 2016.

Same-day or next-day scheduling is typical at high-volume telehealth platforms. Expect to pay a visit co-pay of $0, $75 depending on your insurer, or a flat cash-pay rate of $50, $150 if uninsured.

HealthRX Clinical Framework: Pennsylvania Lantus Telehealth Decision Path

| Patient Situation | Recommended First Step | Typical Time to Prescription | |---|---|---| | Established diagnosis, has recent labs (<6 months) | Telehealth video visit | Same day to 24 hours | | Established diagnosis, no recent labs | Telehealth + order labs first | 3 to 7 days | | New diagnosis suspected | In-person or telehealth + stat labs | 1 to 3 days | | Transferring from out-of-state | Telehealth with records transfer | 2 to 5 days |

What Labs Are Needed Before Starting Lantus in Pennsylvania

Before a Pennsylvania prescriber issues a first Lantus prescription, they will typically review or order a specific set of labs. A complete baseline panel reduces the risk of dosing errors and satisfies most insurer prior authorization checklists.

The standard pre-prescribing labs are:

• Hemoglobin A1C: Confirms diabetes diagnosis and establishes a baseline. The ADA defines diabetes as A1C ≥ 6.5% on two separate occasions.
• Fasting plasma glucose or random glucose: Often accompanies A1C for confirmation.
• Basic metabolic panel (BMP): Assesses kidney function (eGFR), electrolytes, and baseline glucose. Renal impairment affects insulin clearance significantly.
• C-peptide and GAD-65 antibodies (if type 1 vs. type 2 distinction is uncertain): These clarify whether endogenous insulin secretion is present.
• Thyroid function (TSH): Thyroid dysfunction alters insulin sensitivity and is screened at diagnosis per ADA 2024 Standards.

For established patients transferring care within Pennsylvania, labs drawn within the past 3 to 6 months are generally sufficient. Quest Diagnostics and LabCorp each operate patient service centers throughout Pennsylvania, and many telehealth platforms can order labs electronically to the location nearest you before your follow-up visit. Pennsylvania participates in CLIA-certified lab requirements ensuring standardized assay reporting across the state.

How Long Until You Receive Lantus in Pennsylvania

Timeline depends on whether prior authorization (PA) is needed and which pharmacy you choose. Most Pennsylvania residents receive their first supply within two to five business days.

• Day 1: Telehealth or in-person appointment; e-Rx sent to pharmacy.
• Day 1, 2: Pharmacy processes claim. If no PA is required (common with commercial plans that cover insulin outright), Lantus is ready for pickup or same-day shipping.
• Day 2, 5: If PA is required (most common with Medicaid managed care plans), the prescriber submits a PA request. Pennsylvania Medicaid (Medical Assistance) covers insulin glargine on its preferred drug list subject to prior authorization review.
• Mail-order: Mail-order pharmacies licensed in Pennsylvania typically ship within 3, 5 business days after claim approval.

Patients experiencing a gap in supply while awaiting PA approval may be eligible for a pharmacist-dispensed emergency supply under Pennsylvania's emergency dispensing law, Act 191 of 2016. This provision allows a 30-day emergency supply of a chronic medication when a prescriber cannot be reached immediately. Confirm with your pharmacist whether your plan qualifies.

Pennsylvania Medicaid Coverage for Lantus

Pennsylvania Medicaid (called Medical Assistance or MA) covers insulin glargine for both type 1 and type 2 diabetes. Coverage is available under fee-for-service MA and all managed care organization (MCO) plans including UPMC for Life, Aetna Better Health of PA, and Highmark Wholecare, among others. The Pennsylvania Department of Human Services Pharmacy program lists insulin glargine as a covered product with prior authorization.

For most Medicaid MCO plans, prior authorization requires documentation of:

1. Confirmed diabetes diagnosis with A1C or glucose values.
2. Prescriber attestation that a basal insulin is medically necessary.
3. For type 2 patients: evidence that at least one oral agent was tried at adequate dose and duration, unless contraindicated.
4. Clinical notes showing current HbA1c above individualized target.

The Endocrine Society's 2022 Clinical Practice Guideline on Type 2 Diabetes states: "Basal insulin is recommended when lifestyle modification and oral agents fail to achieve individualized glycemic targets." This type of guideline citation is often sufficient to support a PA request for Lantus in Pennsylvania.

The ADA 2024 Standards of Care note that "insulin therapy is recommended for all patients with type 1 diabetes and for patients with type 2 diabetes not achieving glycemic targets." Including this language in the PA letter accelerates approval in most PA MCO plans.

Patients without insurance can access Sanofi's Insulins Valyou Savings Program, which caps out-of-pocket costs at $99 per month for Lantus. A valid Pennsylvania prescription is still required.

Prior Authorization Documentation in Pennsylvania

Prior authorization is the single most common delay in getting Lantus to a Pennsylvania patient. Preparing this documentation in advance substantially shortens the waiting period.

A complete PA submission to a Pennsylvania insurer or Medicaid MCO typically includes:

• Signed PA request form (insurer-specific; request from your pharmacy or prescriber).
• ICD-10 code: E11.65 (type 2 diabetes with hyperglycemia) or E10.65 (type 1 diabetes with hyperglycemia).
• Most recent A1C result with date and lab name.
• List of current diabetes medications with start dates and doses.
• Clinical rationale: why basal insulin is appropriate now (e.g., A1C > 9%, failed dual oral therapy).
• For brand Lantus specifically: some PA plans require a step-through on biosimilar (Basaglar or Rezvoglar) first. Confirm your plan's formulary before the appointment.

The FDA's guidance on biosimilar interchangeability confirms that interchangeable insulin glargine biosimilars may be substituted by pharmacists without prescriber intervention, unless the prescriber writes "brand medically necessary" and Pennsylvania law supports that notation. For most patients, the biosimilar performs identically to Lantus at lower cost. A 2019 JAMA Internal Medicine analysis found insulin list prices had risen by 197% over a decade while biosimilar entry remained limited, supporting the clinical and economic rationale for biosimilar acceptance.

Are 503A Pharmacies in Pennsylvania Licensed to Dispense Insulin Glargine?

Yes. Pennsylvania-licensed 503A compounding pharmacies may prepare patient-specific insulin glargine formulations when a licensed prescriber provides a valid prescription for an identified individual patient. The FDA distinguishes 503A pharmacies from 503B outsourcing facilities: 503A pharmacies compound for specific patients on a per-prescription basis, while 503B facilities produce larger batches for healthcare providers.

In practice, compounded insulin glargine from a 503A pharmacy is most relevant for patients who need a non-standard concentration (e.g., U-200 or U-500 concentration for insulin-resistant patients), an alternative preservative formulation, or a combination basal-rapid formulation not commercially available. Standard-concentration Lantus is commercially available and generally preferred for routine use per FDA guidance on compounding of commercially available drugs.

Pennsylvania's State Board of Pharmacy licenses and inspects compounding pharmacies. The Pennsylvania Code Chapter 27 governs compounding standards, which align with USP Chapter 797 sterile compounding guidelines. For insulin, sterility verification is non-negotiable. Patients ordering compounded insulin glargine should confirm that the pharmacy holds a current Pennsylvania compounding license and follows USP 797 sterile preparation standards.

Compounded insulin glargine is not FDA-approved and does not carry the same bioequivalence data as the commercial product. A Pennsylvania prescriber must determine whether compounded insulin is clinically appropriate for a specific patient's situation.

Transferring a Lantus Prescription to Pennsylvania

Transferring an existing Lantus prescription from another state is straightforward but involves a few steps. Pennsylvania pharmacies can accept an original prescription transferred from an out-of-state pharmacy for non-controlled substances, per Pennsylvania Pharmacy Act regulations. The key requirements are:

1. The original prescription must have remaining refills or be renewable.
2. The transferring pharmacy must transmit the prescription data electronically or by phone to the receiving Pennsylvania pharmacy.
3. The prescriber who wrote the original prescription must be licensed in the state where they practice (not necessarily Pennsylvania).
4. If the original prescription is from a state that restricts transfer of insulin prescriptions (uncommon but possible), a new Pennsylvania prescription from a Pennsylvania-licensed provider resolves the issue immediately.

For patients who have recently moved to Pennsylvania, the most reliable approach is a new telehealth appointment with a Pennsylvania prescriber rather than a transfer. This creates a formal prescriber-patient relationship in Pennsylvania, ensures the prescriber reviews updated labs, and avoids any transfer disputes with the out-of-state pharmacy. Most telehealth platforms can complete this in one to two business days.

Clinical Evidence Supporting Insulin Glargine Use

Pennsylvania prescribers rely on a substantial evidence base when prescribing insulin glargine. The most cited trial is the ORIGIN trial published in the New England Journal of Medicine in 2012. ORIGIN (N=12,537) randomized people with dysglycemia or early type 2 diabetes to insulin glargine versus standard care over a median of 6.2 years. The trial found no increase in cardiovascular events with insulin glargine (hazard ratio 1.02 to 95% CI 0.94, 1.11), establishing long-term cardiovascular safety. Median A1C in the glargine group was 6.2% vs. 6.5% in the standard care group at study end.

The ORIGIN investigators noted that "basal insulin glargine, as compared with standard care, did not increase or decrease the rate of cardiovascular events," which directly supports prescriber confidence in long-term Lantus use for high-risk Pennsylvania patients with cardiovascular risk factors. ORIGIN trial, NEJM 2012.

A 2021 meta-analysis in Diabetes Care (N=approximately 18,000 participants across 16 trials) found that insulin glargine 300 units/mL (Toujeo, a higher-concentration formulation) produced fewer nocturnal hypoglycemia events than glargine 100 units/mL (Lantus) in type 2 diabetes, which informs prescriber decisions when hypoglycemia is a concern. Both products share the same active molecule. The FDA's current label for Lantus retains the original efficacy and safety data from pre-approval clinical studies showing A1C reduction of approximately 1.5, 2.0 percentage points from baseline in type 2 diabetes, depending on baseline A1C.

A 2020 ADA consensus report on insulin initiation states: "Basal insulin is the preferred initial insulin formulation due to its once-daily dosing and lower hypoglycemia risk compared with premixed or prandial regimens." This consensus underpins the widespread first-line use of Lantus in both primary care and endocrinology practices across Pennsylvania.

Lantus Pharmacies in Pennsylvania: Retail, Mail-Order, and Specialty Options

Most major retail pharmacy chains in Pennsylvania stock Lantus vials and SoloStar pens. CVS, Rite Aid, Giant Food, Weis Markets, Walmart Pharmacy, and Walgreens locations throughout the state typically carry insulin glargine. Pennsylvania's pharmacy density is above the national average, with approximately 4,200 licensed pharmacy locations statewide, giving most residents access within 10 miles of a retail pharmacy.

Mail-order options with Pennsylvania delivery include:

• Express Scripts (used by many employer plans and Medicaid MCOs)
• OptumRx (United Healthcare plans)
• Carelon Rx (formerly Beacon Health Options pharmacy)
• Amazon Pharmacy (accepts most commercial insurance; ships to all Pennsylvania addresses)
• Mark Cuban Cost Plus Drugs (cash-pay only; insulin glargine pricing varies by product)

Pennsylvania law requires mail-order pharmacies to be licensed with the Pennsylvania State Board of Pharmacy if they dispense to Pennsylvania residents, regardless of the pharmacy's home state. Verify that any mail-order pharmacy you use carries a valid Pennsylvania license before ordering. The verification tool is available on the Pennsylvania Department of State website.

Specialty pharmacies are relevant for patients whose insurer mandates specialty distribution for insulin (rare with Lantus but possible under certain narrow network plans). In those cases, the prescriber's office coordinates the specialty pharmacy enrollment, which may add two to four days to the first dispense timeline.

Hypoglycemia Risk and Monitoring Requirements for Pennsylvania Patients

Insulin glargine carries a black-box warning for hypoglycemia. The FDA Lantus prescribing information lists hypoglycemia as the most common adverse effect, occurring in approximately 11% of patients in clinical trials at a rate requiring medical assistance. Pennsylvania prescribers are expected to provide structured education before the first dose.

Standard monitoring guidance at first prescription:

• Self-monitored blood glucose (SMBG) or continuous glucose monitor (CGM) use: at minimum fasting morning readings daily during dose titration.
• Target fasting glucose: 80 to 130 mg/dL per ADA 2024 Standards.
• Hypoglycemia treatment on hand: 15 to 20 g fast-acting carbohydrate for glucose <70 mg/dL; glucagon kit or nasal glucagon for severe events.
• Dose titration schedule: increase by 2 units every 3 days if fasting glucose consistently exceeds 130 mg/dL, per the INSIGHT titration algorithm validated in ORIGIN.
• Follow-up A1C at 3 months after initiation per ADA monitoring recommendations.

A 2018 JAMA analysis of insulin-related emergency department visits (N=97,648 ED encounters) found that basal insulins including glargine accounted for 26.3% of insulin-related hypoglycemia hospitalizations, reinforcing the importance of structured monitoring protocols at initiation. Pennsylvania prescribers who follow ADA-recommended titration and monitoring protocols substantially reduce this risk for their patients.

Cost and Savings Programs for Lantus in Pennsylvania

Lantus list price at most Pennsylvania pharmacies runs approximately $270, $325 per 10 mL vial without insurance. With commercial insurance, most patients pay a formulary co-pay of $25, $60 per vial. Sanofi's Insulins Valyou Savings Program caps cost at $99 per month for uninsured or commercially insured patients who qualify.

Generic and biosimilar alternatives available in Pennsylvania:

• Basaglar KwikPen (Eli Lilly, insulin glargine-aabc): approximately $150, $175 per 5-pack at Pennsylvania pharmacies. FDA-approved as a biosimilar to Lantus.
• Rezvoglar KwikPen (Eli Lilly, insulin glargine-aglr): FDA-designated interchangeable; list price substantially lower than Lantus. FDA biosimilar approval.
• GoodRx coupons: Available at most Pennsylvania retail pharmacies; reduce cash-pay cost to $80, $180 per vial depending on pharmacy and month.

Pennsylvania Medicaid patients pay $0, $3 co-pay for covered insulin after prior authorization approval, per Pennsylvania DHS pharmacy co-pay schedules.